Eur J Cancer: The role of local therapy in the presence of isolated metastases in melanoma immunotherapy: a multicenter retrospective study

Immune checkpoint inhibitors (ICI) can give metastatic melanoma a longer period of tumor control.

Immune checkpoint inhibitors (ICI) can give metastatic melanoma a longer period of tumor control.

The study retrospectively collected non-uveal melanoma patients in 17 research centers in 9 countries from 2010 to 2019, who used immunotherapy for more than 12 weeks and achieved stable (SD) or partial remission (PR) or complete remission ( CR), and then an isolated metastasis occurs during or after immunotherapy.

The study retrospectively collected non-uveal melanoma patients in 17 research centers in 9 countries from 2010 to 2019, who used immunotherapy for more than 12 weeks and achieved stable (SD) or partial remission (PR) or complete remission ( CR), and then an isolated metastasis occurs during or after immunotherapy.

Characteristics of metastasis during and after treatment

 Characteristics of metastasis during and after treatment

The study included 294 patients, of which 143 had isolated metastasis during immunotherapy and 151 after treatment.

The study included 294 patients, of which 143 had isolated metastasis during immunotherapy and 151 after treatment.

In the overall population, the median PFS1 was 13 months (95% CI 11-14), the median PFS2 was 14 months (95% CI 10-17), and the median TTSP was 33 months (95% CI 29-37) ).

Prognosis comparison of the total population, during and after treatment

For patients who progressed in the treatment of immunotherapy, the median PFS1 was 11 months (95% CI 9-12); the median PFS2 was 16 months (95% CI 10-23); the median TTSP was 29 months (95% CI 10-23).

For patients who progressed in the treatment of immunotherapy, the median PFS1 was 11 months (95% CI 9-12); the median PFS2 was 16 months (95% CI 10-23); the median TTSP was 29 months (95% CI 10-23).

Prognosis of progress in immunotherapy

For patients who progressed after immunotherapy, median PFS1 was 17 months (95% CI 14-21); median PFS2 was 10 months (95% CI 6-14); median TTSP was 35 months (95% CI 30-40); the median OS was not reached; the 3-year OS rate was 82% (95% CI 76-89).

For patients who progressed after immunotherapy, median PFS1 was 17 months (95% CI 14-21); median PFS2 was 10 months (95% CI 6-14); median TTSP was 35 months (95% CI 30-40); the median OS was not reached; the 3-year OS rate was 82% (95% CI 76-89).

Prognosis of progression after immunotherapy

In summary, for patients with advanced melanoma, when immunotherapy responds and isolated metastases appear after treatment, local treatment can provide patients with long-term clinical benefits.

In summary, for patients with advanced melanoma, when immunotherapy responds and isolated metastases appear after treatment, local treatment can provide patients with long-term clinical benefits.

Original source:

Judith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Eur J Cancer.
2021 May 7;151:72-83 .
doi: 10.
1016/j.
ejca.
2021.
04.
003.
Online ahead of print.

Judith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Eur J Cancer.
2021 May 7;151:72-83 .
doi: 10.
1016/j.
ejca.
2021.
04.
003.
Online ahead of print.


Leave a message here